Shire Articles
EUROPEAN AND LONDON STOCK COMMENT
26 March 1997
Shire Plans US Acquisition For Around $170 Million
3 March 1997
Progress With Shire's Lambda And Hyacne
23 December 1996
Galanthamine Enters Ph III In USA For Alzheimer's
28 October 1996
"Progress On All Fronts" At Shire Pharmaceuticals
7 October 1996
Shire's Alzheimer's Drug Shows Promise
5 August 1996
Shire: An Emerging Firm With A Difference
20 May 1996
Shire Pharmaceuticals Makes Interim Progress
25 March 1996
European Alzheimer's/ Dementia markets
11 March 1996
-Shire Pharmaceuticals Flotation
19 February 1996
Shire Pharmaceuticals: Stock Market News
5 February 1996
Shire Signs Alzheimer's Drug Rights To Janssen
29 January 1996
Shire Pharmaceuticals adds to Irish drugs sales initiative
23 October 1995
Corporate News In Brief
25 September 1995
Chiroscience: galanthamine development
11 September 1995
Shire's Galanthamine Ahead Of Itself
24 July 1995
Shire and J Matthey codevelopment of kidney drug
26 June 1995
Shire gives Searle South African deal
29 May 1995
L10 Million Interim Funding For Shire Pharma
6 March 1995
Shire Expands Product Lines
13 February 1995
Shire And Sekisui Sign Joint Agreement
23 January 1995
Shire Pharmaceuticals License Application
9 January 1995
Shire Pharma Sites Marketing In Eire
2 January 1995
Shire Pharma Acquires Galanthamine Rights
5 December 1994
AUSTRALIA (KINGAROY) PHARMA BOOM FORECAST
6 December 1993
OPPORTUNITIES IN UK BIOSCIENCE SECTOR
21 June 1993
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
